Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Slayden, O.D.
Right arrow Articles by Brenner, R.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slayden, O.D.
Right arrow Articles by Brenner, R.M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 16, No. 8, 1562-1574, August 2001
© 2001 European Society of Human Reproduction and Embryology

Reversible suppression of menstruation with progesterone antagonists in rhesus macaques

O.D. Slayden1, K. Chwalisz2,3 and R.M. Brenner1,4

1 Division of Reproductive Sciences, Oregon Regional Primate Research Center, Beaverton OR 97006, USA and 2 Jenapharm, GmbH and Co. KG, Jena, Germany 07745

BACKGROUND: A reliable means of menstrual suppression would greatly improve the quality of life for women. Information is lacking on the direct endometrial effects and appropriate dosages of new antiprogestins that may be useful for this purpose. METHODS: The current work evaluated three different systems in macaque monkeys. First, the range of doses of two relatively new antiprogestins, ZK 137 316 and ZK 230 211, that would block progesterone action directly on the endometrium in artificially cycled, spayed rhesus macaques; second, the direct endometrial effects of ZK 230 211, a type III antiprogestin; and third, investigation of whether endometrial-suppressive doses administered chronically to intact, cycling monkeys could be used for reversible, menstrual suppression. RESULTS: The results in naturally cycling animals showed that ZK 137 316 blocked menstruation in all animals, but doses of 0.05 mg/kg blocked ovulation in 55.5% of animals and doses of 0.1 mg/kg blocked ovulation in 66.6% of the animals. However, all doses of ZK 230 211 that blocked menstruation also blocked ovulation. All progesterone antagonist (PA)-treated animals, regardless of dose, maintained normal follicular phase concentrations of oestradiol and returned to normal menstrual cyclicity within 15–41 days post-treatment.Therefore ZK 137 316, depending on dose, can allow ovulation but block menstruation, while ZK 230 211, a much more potent PA, blocks both ovulation and menstruation at all effective doses. Both PAs block unopposed oestrogenic action on the endometrium through their antiproliferative effects. CONCLUSIONS: Reversible amenorrhoea can be achieved with these two PAs, and they can protect the endometrium from the effects of unopposed oestrogen whether or not ovulation is blocked. Chronic, low dose PA treatment may provide a new option for women who wish to suppress their menstrual periods.

Key words: endometrium/macaque/menstruation/ovulation/progesterone antagonists

3 Present address: TAP Pharmaceutical Products, Lake Forest, IL 60045, USA

4 To whom correspondence should be addressed. E-mail: brennerr{at}ohsu.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Toxicol PatholHome page
E. van Esch, J. M. Cline, E. Buse, and G. F. Weinbauer
The Macaque Endometrium, with Special Reference to the Cynomolgus Monkey (Macaca fascicularis)
Toxicol Pathol, December 1, 2008; 36(7_suppl): 67S - 100S.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. de Giorgio-Miller, P. Bungay, M. Tutt, J. Owen, D. Goodwin, and N. Pullen
The Translational Pharmacology of a Novel, Potent, and Selective Nonsteroidal Progesterone Receptor Antagonist, 2-[4-(4-Cyano-phenoxy)-3,5-dicyclopropyl-1H-pyrazol-1-yl]-N-methylacetamide (PF-02367982)
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 78 - 87.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
O. Heikinheimo, S. Vani, O. Carpen, A. Tapper, P. Harkki, E.-M. Rutanen, and H. Critchley
Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study
Hum. Reprod., September 1, 2007; 22(9): 2515 - 2522.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
O.D. Slayden, M.B. Zelinski, K. Chwalisz, H. Hess-Stumpp, and R.M. Brenner
Chronic progesterone antagonist-estradiol therapy suppresses breakthrough bleeding and endometrial proliferation in a menopausal macaque model
Hum. Reprod., December 1, 2006; 21(12): 3081 - 3090.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
K. Chwalisz, M. C. Perez, D. DeManno, C. Winkel, G. Schubert, and W. Elger
Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis
Endocr. Rev., May 1, 2005; 26(3): 423 - 438.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R. M. Brenner, O. D. Slayden, W. H. Rodgers, H. O.D. Critchley, R. Carroll, X. J. Nie, and K. Mah
Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium
Hum. Reprod., June 1, 2003; 18(6): 1185 - 1193.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
S.M. Borman, K.M. Schwinof, C. Niemeyer, K. Chwalisz, R.L. Stouffer, and M.B. Zelinski-Wooten
Low-dose antiprogestin treatment prevents pregnancy in rhesus monkeys and is reversible after 1 year of treatment
Hum. Reprod., January 1, 2003; 18(1): 69 - 76.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.